SCHEMBL4521340

SCHEMBL4521340

COCCNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccccc3CNC(=O)Nc3cc(C(C)(C)C)nn3-c3cccc(OCCOC4CCCCO4)c3)c(Cl)c2=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 0.38
GSK3A P49840 4/20 0.38
SRC P12931 3/20 0.38
SYK P43405 3/20 0.38
CDK8 P49336 5/20 0.36
PKN2 Q16513 3/20 0.36
RET P07949 3/20 0.36
PDGFRA P16234 3/20 0.36
MAPK9 P45984 2/20 0.36
MAPK13 O15264 2/20 0.34
MAPK12 P53778 2/20 0.34
MAPK11 Q15759 2/20 0.34
GRK5 P34947 2/20 0.33
PRKX P51817 2/20 0.33
TYRO3 Q06418 2/20 0.33
NTRK2 Q16620 2/20 0.33
PRKAA1 Q13131 1/20 0.33
ROCK1 Q13464 1/20 0.33
TAOK1 Q7L7X3 1/20 0.33
AURKA O14965 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4524422 0.95 MAPK14 (0.37) MAPK14GSK3ASRCSYKCDK8
SCHEMBL4510417 0.94 MAPK14 (0.38) MAPK14GSK3ASRCSYKMAPK13
SCHEMBL4503425 0.94 MAPK14 (0.39) MAPK14MAPK13MAPK12MAPK11AURKA
SCHEMBL13678569 0.90 MAPK14 (0.36) MAPK14MAPK9AURKANTRK1
SCHEMBL4514157 0.90 MAPK14 (0.37) MAPK14GSK3ASRCSYKCDK8
SCHEMBL13678568 0.90 MAPK14 (0.37) MAPK14MAPK9MAPK13MAPK12MAPK11
SCHEMBL13678590 0.89 MAPK14 (0.45) MAPK14GSK3ASRCSYKCDK8
SCHEMBL4497908 0.89 MAPK14 (0.38) MAPK14RETMAPK9MAPK12MAPK11
SCHEMBL4496970 0.89 MAPK14 (0.38) MAPK14RETMAPK9MAPK13MAPK12
SCHEMBL4502277 0.86 MAPK14 (0.37) MAPK14RETMAPK9MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 EP disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PDXK, UMPS, CDK2 MAPK14 117/4885GSK3A 2219/4885SRC 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.